Log In Sign up
The largest database of trusted experimental protocols

Lncap

Manufactured by Selleck Chemicals
Visit Supplier
Sourced in United States

LNCaP is a human prostate adenocarcinoma cell line derived from the left supraclavicular lymph node metastasis of a 50-year-old Caucasian male. It is a commonly used in vitro model for the study of prostate cancer.

Automatically generated - may contain errors

Lab products found in correlation

Lncap, by American Type Culture Collection (3 mentions) Enzalutamide, by Selleck Chemicals (2 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Lncap, by Shanghai Zhong Qiao Xin Zhou Biotechnology (1 mentions) Penicilin streptomycin, by Thermo Fisher Scientific (1 mentions) Bicalutamide, by Selleck Chemicals (1 mentions) Rpmi 1640, by Thermo Fisher Scientific (1 mentions) Mdv3100, by Selleck Chemicals (1 mentions) Vcap prostate cancer cells, by American Type Culture Collection (1 mentions) Gentamicin, by Thermo Fisher Scientific (1 mentions) Amphotericin b, by Wisent (1 mentions) Du145, by Selleck Chemicals (1 mentions) Olaparib, by Selleck Chemicals (1 mentions) Du145, by American Type Culture Collection (1 mentions) Htb 81, by American Type Culture Collection (1 mentions) Rpmi 1640 medium, by Wisent (1 mentions) Crl 174, by American Type Culture Collection (1 mentions) Rwpe 1, by American Type Culture Collection (1 mentions) Mycoalert, by Lonza (1 mentions) 22rv1 pca, by American Type Culture Collection (1 mentions)

5 protocols using lncap

1

Establishing Bicalutamide-Resistant Prostate Cancer Cells

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Human prostate cancer cells (PC3, DU145, LNCap) are purchased by two agent companies from the Cell Resource Center of Shanghai Academy of Life Sciences, Chinese Academy of Sciences. The PC3 and LNCap cells were purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Company. The DU145 cells were purchased from Shanghai Biowing Applied Biotechnology Company. bicalutamide-resistant (Bica-R) cells was constructed early in our group [33 (link)]. The LNCap cells, one of the androgen-dependent prostate cancer cell strains, were treated with bicalutamide (10 μM) (Selleck Chemicals, Houston, TX, USA), respectively for at least 6 months to generate bicalutamide-resistant cells. Cells were cultured in RPMI-1640 (Gibco, USA) medium supplemented with 10% fetal bovine serum (Gibco, USA), 1% penicilin/streptomycin ((Life Technologies, Carlsbad CA) in a humidified incubator of 5% CO2 at 37 °C.
Fan J., Fan Y., Wang X., Niu L., Duan L., Yang J., Li L., Gao Y., Wu X, & Luo C. (2019). PLCε regulates prostate cancer mitochondrial oxidative metabolism and migration via upregulation of Twist1. Journal of Experimental & Clinical Cancer Research : CR, 38, 337.
+ Open protocol
+ Expand
2

Prostate Cancer Cell Line Maintenance and Authentication

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
LNCaP (clone FGC), PC-3, and VCaP prostate cancer cells were purchased from American Type Culture Collection. The MR49F cell line was a kind gift from Dr Martin Gleave (Vancouver Prostate Center, Vancouver, BC). All cells were maintained at 37°C in a humidified atmosphere containing 5% CO2. LNCaP and PC-3 cells were cultured in the Roswell Park Memorial Institute-1640 (RPMI-1640) media supplemented with 10% fetal bovine serum (FBS) and VCaP cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) media supplemented with 10% FBS. The enzalutamide-resistant derivative of the LNCaP cell line, MR49F, was cultured in RPMI-1640 media supplemented with 10% FBS and 10 μM MDV3100.30 (link) MDV3100 was purchased from SelleckChem (S1250; Houston, TX). All cell lines used were authenticated by short tandem repeat analyses at the Johns Hopkins Genetic Resources Core Facility. BMPC-1 cells were as in Markowski et al31 (link) and were cultured in DMEM supplemented with 10% FBS.
BMH-21 was synthesized at the Drug Discovery Division, Lieber Institute (Baltimore, MD), and the chemical structure and purity were verified using liquid chromatography-mass spectrometry and proton nuclear magnetic resonance.
Low J.Y., Sirajuddin P., Moubarek M., Agarwal S., Rege A., Guner G., Liu H., Yang Z., De Marzo A.M., Bieberich C, & Laiho M. (2019). Effective targeting of RNA polymerase I in treatment-resistant prostate cancer. The Prostate, 79(16), 1837-1851.
+ Open protocol
+ Expand
3

Establishing Olaparib-Resistant Prostate Cancer Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human PC cell lines, LNCaP (RRID:CVCL_0395) and DU145 (RRID:CVCL_0105), were purchased from the American Type Culture Collection (Manassas, VA, USA; ATCC CRL-174 and ATCC HTB- 81, respectively). The LNCaP C4-2B, denoted C4-2B in the study, (RRID:CVCL_4784) cell line was kindly gifted by Dr. Martin Gleave (Vancouver Prostate Centre, BC, Canada). All cell lines were verified by short tandem repeat (STR). Cell lines were cultured in RPMI 1640 medium (Wisent Inc., St-Bruno, QC, Canada; 350-000-EL) supplemented with 10% fetal bovine serum (FBS; Wisent Inc., St-Bruno, QC, Canada; 098–150), 0.5 µg/mL amphotericin B (Wisent Inc., St-Bruno, QC, Canada; 450–105-QL), and 50 µg/mL gentamicin (Life Technologies Inc., Carlsbad, CA, USA; 15710064). All cells were grown in 5% CO2 at 37 °C. OR cells derived from LNCaP, C4-2B and DU145 were obtained by culturing parental cell lines in increasing concentrations (0.5 to 70 µM) of olaparib (Selleckchem, Conshohocken, PA, USA; AZD2281) for 6 months. Doubling time and cell morphology were determined using the IncuCyteTM Live-Cell Imaging System (Essen BioScience, Inc., Ann Arbor, MI, USA).
Cahuzac M., Péant B., Mes-Masson A.M, & Saad F. (2022). Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance. Cancers, 14(16), 3877.
+ Open protocol
+ Expand
4

Prostate Cancer Cell Lines: Cultivation and ADT

Check if the same lab product or an alternative is used in the 5 most similar protocols
RWPE-1 (CRL-11609), LNCaP (CRL-1740), VCaP (CRL-2876), and PC3 (CRL-1435) were obtained from ATCC. C4-2, C4-2B and DU145 were a gift from the LaBonte Wilson group, Queen’s University Belfast. Cells were cultured in recommended growth medium supplemented with 10% FBS/1% penicillin–streptomycin and maintained at 37 °C/5% CO2. To mimic ADT, LNCaP were cultured in charcoal-stripped FBS-supplemented culture medium (CSFBS), or, treated with Enzalutamide (10 µM, ENZ, s1250, Selleck Chemicals) diluted in standard FBS-containing medium. Mycoplasma testing was performed bi-annually (MycoAlert, LT07-217, Lonza).
McKerr N., Mohd-Sarip A., Dorrian H., Breen C., A. James J., McQuaid S., Mills I.G, & McCloskey K.D. (2023). CACNA1D overexpression and voltage-gated calcium channels in prostate cancer during androgen deprivation. Scientific Reports, 13, 4683.
+ Open protocol
+ Expand
5

Cell Culture and Enzalutamide Resistance

Check if the same lab product or an alternative is used in the 5 most similar protocols
LNCaP, PC3, C4-2 and 22RV-1 PCa cells were purchase from ATCC and maintained in Tissue and Cell Culture Core Facility at Baylor College of Medicine. Cells were cultured in RPMI1640 medium with 10% FBS and antibiotics (100 μg ml−1 streptomycin and 100 U ml−1 penicillin G) in a humidified atmosphere of 5% CO2 and 95% air at 37 °C. LNCaP-abl cells were cultured in RPMI1640 medium with 10% charcoal-stripped FBS. Fresh medium were changed after three days of incubation. Cells were routinely checked for mycoplasma contamination by using MycoAlert Mycoplasma Detection Kit (LONZA). Short-tandem repeat analysis was performed by the service of Core Facility in MD Anderson Cancer Center for the authentication of the cell lines. For the enzalutamide experiment, 2 × 103 LNCaP parental and enzalutamide-resistant cells were plated into 96-well-plates and treated with 10 μM enzalutamide (purchased from Selleck Chemicals) for the indicated time points.
Lin S.C., Kao C.Y., Lee H.J., Creighton C.J., Ittmann M.M., Tsai S.J., Tsai S.Y, & Tsai M.J. (2016). Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. Nature Communications, 7, 11418.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!